Clinical Trial Update: Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the effect of infliximab on the efficacy of Peg-Intron/ribavirin in chronic hepatitis C has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Infliximab (infliximab)
• PEG Intron (pegylated interferon alfa-2b)
• Ribavirin (ribavirin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C, Chronic | Phase 3 | Status: COMPLETED